<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="(CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Background: Currently, the immunogenicity of" exact="influenza" post="vaccines is assessed by detecting an increase of hemagglutination"/>
 <result pre="As neuraminidase (NA)-based immunity may be significant in protecting against" exact="influenza" post="infection, detection of neuraminidase inhibiting (NI) antibodies may improve"/>
 <result pre="(NI) antibodies may improve the assessment of the immunogenicity of" exact="influenza" post="vaccines. Methods: We investigated the immune response to NA"/>
 <result pre="immune response to NA in people after immunization with live" exact="influenza" post="vaccines (LAIVs). A number of A/H7NX or A/H6NX viruses"/>
 <result pre="can provide a more complete assessment of LAIV immunogenicity. live" exact="influenza" post="vaccine immunogenicity neuraminidase inhibiting antibody 1. Introduction The determination"/>
 <result pre="The determination of antibodies that inhibit neuraminidase (NA) in the" exact="influenza" post="virus (the genus Influenzavirus, the family Orthomyxoviridae) is of"/>
 <result pre="used when examining the levels of collective immunity to new" exact="influenza" post="viruses, and for assessing the immunogenicity of influenza vaccines"/>
 <result pre="to new influenza viruses, and for assessing the immunogenicity of" exact="influenza" post="vaccines [1]. Currently, the immunogenicity of influenza vaccines is"/>
 <result pre="the immunogenicity of influenza vaccines [1]. Currently, the immunogenicity of" exact="influenza" post="vaccines is assessed by detecting an increase of hemagglutination"/>
 <result pre="significant in protection against a new antigenic variant of an" exact="influenza" post="virus, detection of neuraminidase inhibiting (NI) antibodies may improve"/>
 <result pre="may improve the study of the immunogenicity of newly developed" exact="influenza" post="vaccines. In the present study, we investigated the formation"/>
 <result pre="formation of NI antibodies in people after immunization with live" exact="influenza" post="vaccines (LAIVs) of pandemic and potentially pandemic subtypes. The"/>
 <result pre="antibodies and, therefore, to develop criteria for the immunogenicity of" exact="influenza" post="vaccine assessment based on the evaluation of NI antibodies."/>
 <result pre="based on the evaluation of NI antibodies. To obtain reassortant" exact="influenza" post="A vaccine viruses, a cold-adapted â€œmaster donor strainâ€� (MDS)"/>
 <result pre="genes of surface glycosylated proteinsâ€&quot; hemagglutitin (HA) and NAâ€&quot;from epidemic" exact="influenza" post="viruses. LAIVs have been used in Russia since the"/>
 <result pre="years of age, and 40% in adults [5,6]. As seasonal" exact="influenza" post="vaccines cannot protect against infection with avian influenza viruses,"/>
 <result pre="[5,6]. As seasonal influenza vaccines cannot protect against infection with" exact="avian influenza" post="viruses, the World Health Organization (WHO) carries out monitoring"/>
 <result pre="As seasonal influenza vaccines cannot protect against infection with avian" exact="influenza" post="viruses, the World Health Organization (WHO) carries out monitoring"/>
 <result pre="(WHO) carries out monitoring and analysis of potentially pandemic zoonotic" exact="influenza" post="viruses in the development of appropriate vaccines [7]. In"/>
 <result pre="formation of antibodies to NA of pandemic and potentially pandemic" exact="influenza" post="viruses after LAIV immunization. 2. Materials and Methods 2.1."/>
 <result pre="before and 21 days after vaccination with seasonal trivalent live" exact="influenza" post="vaccine (LAIV) 2005â€&quot;2006. The trivalent vaccine was manufactured by"/>
 <result pre="Center collected in the 2016, and the paired sera from" exact="influenza" post="convalescents provided by the Institute of Influenza. The patients"/>
 <result pre="A/17/mallard/Netherlands/00/95 (H7N3) vaccine strain, we used the A/tern/South Africa/61 (H5N3)" exact="influenza" post="virus. All viruses were cultured in the allantoic cavity"/>
 <result pre="Results Table 3 presents antibody levels (GMTs) against both main" exact="influenza" post="glycoproteinsâ€&quot;HA and NAâ€&quot;detected before vaccination and after revaccination with"/>
 <result pre="after revaccination with LAIVs developed against pandemic and potentially pandemic" exact="influenza" post="viruses. According to the HI test and ELLA, the"/>
 <result pre="the presence of NI antibodies, including the N1 of the" exact="avian influenza" post="virus A/Vietnam/1203/04 (H5N1) and the drift variant of the"/>
 <result pre="presence of NI antibodies, including the N1 of the avian" exact="influenza" post="virus A/Vietnam/1203/04 (H5N1) and the drift variant of the"/>
 <result pre="drift variant of the pandemic virus A(H1N1)pdm09â€&quot;the A/South Africa/3626/2013 (H1N1)pdm09" exact="influenza" post="virus (Table 4). The lowest preexisting NI antibody levels"/>
 <result pre="NI antibody levels were revealed against A/Anhui/1/13(H7N9) and A/South Africa/3626/13(H1N1)pdm09" exact="influenza" post="viruses (0% and 7% of persons with NI antibody"/>
 <result pre="against A/H1N1pdm09, but also for the NA of the A/Vietnam/1203/04(H5N1)" exact="avian influenza" post="virus. In 2011, 46% of the examined volunteers had"/>
 <result pre="A/H1N1pdm09, but also for the NA of the A/Vietnam/1203/04(H5N1) avian" exact="influenza" post="virus. In 2011, 46% of the examined volunteers had"/>
 <result pre="A/H1N1pdm09 had been recommended for inclusion in the composition of" exact="influenza" post="vaccines in the 2016â€&quot;2017 influenza season (https://www.who.int/influenza/vaccines/virus/recommendations/summary_a_h1n1pdm09_cvv_nh1617.pdf). From 2009,"/>
 <result pre="inclusion in the composition of influenza vaccines in the 2016â€&quot;2017" exact="influenza" post="season (https://www.who.int/influenza/vaccines/virus/recommendations/summary_a_h1n1pdm09_cvv_nh1617.pdf). From 2009, A/California/7/09(H1N1)pdm09-like viruses circulated, which, from"/>
 <result pre="to NA, which may be associated with first contacts with" exact="influenza" post="viruses [24]. Figure 1 demonstrates the NI and HI/MN"/>
 <result pre="previously obtained data on NI antibodies as independent indicators of" exact="influenza" post="immunity, other than hemagglutination inhibiting antibodies [25]. In the"/>
 <result pre="increase in NI antibodies, not only to homologous seasonal A/H1N1" exact="influenza" post="virus, but also to the antigenically distinct variants A/California/7/09"/>
 <result pre="(H1N1)pdm09 and A/Vietnam/1203/04(H5N1). Antibody levels to the A/New Caledonia/20/99 (H1N1)" exact="influenza" post="virus to some extent correlated with titers of the"/>
 <result pre="0.60; n = 56; p &amp;lt; 0.001) and avian A/H5N1" exact="influenza" post="virus (rs = 0.46; n = 56; p &amp;lt;"/>
 <result pre="acid sequences of avian A/H5N1 and epidemic and pandemic A/H1N1pdm09" exact="influenza" post="strains demonstrated the higher homology between amino acid sequences"/>
 <result pre="volunteers examined in 2011; that is, after the pandemic A/H1N1pdm09" exact="influenza" post="virus entered circulation. The mean NI anti-H5N1/2004 antibody titer"/>
 <result pre="we analyzed the NI antibody content in patients with confirmed" exact="influenza" post="A infection, and recipients of A/17/California/09/38 (H1N1)pdm09 LAIV with"/>
 <result pre="statistically significant (p &amp;lt; 0.0001). 4. Discussion LAIVs against seasonal" exact="influenza" post="are harmless and cause persistent homologous responses to wild-type"/>
 <result pre="influenza are harmless and cause persistent homologous responses to wild-type" exact="influenza" post="viruses [4]. Owing to the high variability of influenza"/>
 <result pre="wild-type influenza viruses [4]. Owing to the high variability of" exact="influenza" post="HA, each vaccine formulation should be updated almost annually."/>
 <result pre="each vaccine formulation should be updated almost annually. Although licensed" exact="influenza" post="vaccines are primarily designed to provide homotypic protection, studies"/>
 <result pre="designed to provide homotypic protection, studies show that immunization with" exact="influenza" post="vaccines or natural infections with seasonal influenza A strains"/>
 <result pre="that immunization with influenza vaccines or natural infections with seasonal" exact="influenza" post="A strains induce serum cross-reactive antibodies to antigenically different"/>
 <result pre="of viruses [26,27]. Traditionally, the assessment of the immunogenicity of" exact="influenza" post="vaccines is carried out by assessing the level of"/>
 <result pre="of the virus, the HA. The study of antibodies to" exact="influenza" post="NA is useful when influenza viruses with new HAs"/>
 <result pre="The study of antibodies to influenza NA is useful when" exact="influenza" post="viruses with new HAs appear in circulation, and the"/>
 <result pre="determining NA-inhibiting antibodies. To avoid non-specific reactions with antibodies to" exact="influenza" post="A, viruses of subtype H7 and H6 are used"/>
 <result pre="The protective role of serum antibodies to the NA of" exact="influenza" post="viruses was discovered in the 1970s. During the outbreak"/>
 <result pre="discovered in the 1970s. During the outbreak of Hong Kong" exact="influenza" post="in 1968, the frequency of infection with the A/H3N2"/>
 <result pre="it was found that NA antibodies reduce the severity of" exact="influenza" post="infection in humans [30]. In animal experiments, it was"/>
 <result pre="In 2009, the WHO announced the emergence of a new" exact="influenza" post="pandemic caused by the influenza A/H1N1pdm09 virus, which had"/>
 <result pre="the emergence of a new influenza pandemic caused by the" exact="influenza" post="A/H1N1pdm09 virus, which had not previously been isolated from"/>
 <result pre="announcement of the pandemic, studies of the immune status against" exact="influenza" post="viruses in various populations began [33]. It was revealed"/>
 <result pre="that some people have cross-reacting antibodies to the NA of" exact="influenza" post="viruses with new HA subtypes, resulting from contacts with"/>
 <result pre="a titer of â‰¥1:40 significantly reduced the duration of seasonal" exact="influenza" post="A virus shedding in adults [35]. Age-related differences in"/>
 <result pre="N1 subtype [24]. Despite the fact that the NA of" exact="influenza" post="A/H1N1 and A/H5N1 strains differs in antigenic properties and"/>
 <result pre="the spatial structure of the NA of several subtypes of" exact="influenza" post="A virus and the only subtype of influenza B"/>
 <result pre="subtypes of influenza A virus and the only subtype of" exact="influenza" post="B virus is known, and the mechanisms of the"/>
 <result pre="by amino acids that are conserved in animal and human" exact="influenza" post="A viruses of various subtypes, as well as influenza"/>
 <result pre="human influenza A viruses of various subtypes, as well as" exact="influenza" post="B viruses. NA has often been seen as a"/>
 <result pre="seronegative population. The HI and NI antibody titers to A/California/7/09(H1N1)pdm09" exact="influenza" post="virus after natural infection were higher compared with LAIV"/>
 <result pre="with an increased level of NI antibodies to the H1N1/2009pdm09" exact="influenza" post="virus, but also when vaccinated with a seasonal LAIV."/>
 <result pre="[30]. Higher proportions of pre-existing NI antibodies against distant A/H2N2" exact="influenza" post="viruses among elderly volunteers compared with younger people suggests"/>
 <result pre="for priority vaccination. The absence of antibodies to the A/H7N9" exact="influenza" post="virus among people aged 18â€&quot;49 indicates their susceptibility to"/>
 <result pre="coincidence of the serum immune response to the two surface" exact="influenza" post="antigens indicates the need to use ELLA to more"/>
 <result pre="to use ELLA to more fully characterize the immunogenicity of" exact="influenza" post="vaccines. 5. Conclusions A number of LAIVs developed against"/>
 <result pre="A number of LAIVs developed against pandemic and potentially pandemic" exact="influenza" post="viruses have effectively elicited an immune response in the"/>
 <result pre="increase in inhibition of the hemagglutinating and neuraminidase activity of" exact="influenza" post="viruses, as assessed by post-vaccination sera, was revealed. Combining"/>
 <result pre="antigenically distant strains. Low preexisting NI antibodies against newly emerged" exact="influenza" post="viruses may indicate a high-risk population for priority vaccination."/>
 <result pre="of Influenza, Saint Petersburg, Russia, for providing the sera from" exact="influenza" post="convalescents. Author Contributions Conceptualization, Y.D. and T.S.; methodology, T.S."/>
 <result pre="References References 1.KrammerF.FouchierR.A.EichelbergerM.C.WebbyR.J.Shaw-SalibaK.WanH.WilsonP.C.CompansR.W.SkountzouI.MontoA.S.NAction! How can neuraminidase-based immunity contribute to better" exact="influenza" post="virus vaccines?MBio20189e02332-1710.1128/mBio.02332-17 2.AlexandrovaG.I.BudilovskyG.N.KovalT.A.PolezhaevF.I.GarmashovaL.M.GhendonY.Z.RomanovaY.R.SmorodintsevA.A.Study of live recombinant cold-adapted influenza bivalent"/>
 <result pre="to better influenza virus vaccines?MBio20189e02332-1710.1128/mBio.02332-17 2.AlexandrovaG.I.BudilovskyG.N.KovalT.A.PolezhaevF.I.GarmashovaL.M.GhendonY.Z.RomanovaY.R.SmorodintsevA.A.Study of live recombinant cold-adapted" exact="influenza" post="bivalent vaccine of type A for use in children:"/>
 <result pre="in children: An epidemiological control trialVaccine1986411411810.1016/0264-410X(86)90049-63524050 3.AlexandrovaG.I.MaassabH.F.KendalA.P.MedvedevaT.E.EgorovA.Y.KlimovA.I.CoxN.J.Laboratory properties of cold-adapted" exact="influenza" post="B live vaccine strains developed in the US and"/>
 <result pre="Immunization Practicesâ€™ controversial recommendation against the use of live attenuated" exact="influenza" post="vaccine is based on a biased study design that"/>
 <result pre="VecchiaC.Influenza vaccine in healthy children: A meta-analysisVaccine2005232851286110.1016/j.vaccine.2004.11.05315780733 6.KendalA.P.Cold-adapted live attenuated" exact="influenza" post="vaccines developed in Russia: Can they contribute to meeting"/>
 <result pre="in Russia: Can they contribute to meeting the needs for" exact="influenza" post="control in other countries?Eur. J. Epidemiol.19971359160910.1023/A:10073275058629258574 7.WHO Technical Report."/>
 <result pre="mice induced by live-attenuated or inactivated vaccines against highly pathogenic" exact="influenza" post="A (H5N1) virusesVaccine2006246588659310.1016/j.vaccine.2006.05.03917030078 9.RudenkoL.DeshevaJ.KorovkinS.MironovA.RekstinA.GrigorievaE.DoninaS.GambaryanA.KatlinskyA.Safety and immunogenicity of live attenuated"/>
 <result pre="influenza A (H5N1) virusesVaccine2006246588659310.1016/j.vaccine.2006.05.03917030078 9.RudenkoL.DeshevaJ.KorovkinS.MironovA.RekstinA.GrigorievaE.DoninaS.GambaryanA.KatlinskyA.Safety and immunogenicity of live attenuated" exact="influenza" post="reassortant H5 vaccine (phase I-II clinical trials)Influenza Other Respir."/>
 <result pre="clinical trials)Influenza Other Respir. Viruses2008220320910.1111/j.1750-2659.2008.00064.x19453396 10.RudenkoL.Van Den BoschH.KiselevaI.MironovA.NaikhinA.LarionovaN.BushmenkovD.Live attenuated pandemic" exact="influenza" post="vaccine: Clinical studies on A/17/California/ 2009/38 (H1N1) and licensing"/>
 <result pre="and licensing of the Russian-developed technology to WHO for pandemic" exact="influenza" post="preparedness in developing countriesVaccine201129A40A4410.1016/j.vaccine.2011.04.12221684428 11.DeshevaY.SmolonoginaT.RudenkoL.Detection of anti-neuraminidase antibody in"/>
 <result pre="of anti-neuraminidase antibody in preclinical and clinical studies of live" exact="influenza" post="vaccineInfluenza Other Respir. Viruses20115370 12.DeshevaJ.RudenkoL.RekstinA.SwayneD.E.CoxN.J.KlimovA.I.Development of candidate H7N3 live"/>
 <result pre="Other Respir. Viruses20115370 12.DeshevaJ.RudenkoL.RekstinA.SwayneD.E.CoxN.J.KlimovA.I.Development of candidate H7N3 live attenuated coldâ€&quot;adapted" exact="influenza" post="vaccineProceedings of the International Conference on Options for the"/>
 <result pre="June 2007 13.RudenkoL.KiselevaI.NaykhinA.N.ErofeevaM.StukovaM.DoninaS.PetukhovaG.PisarevaM.KrivitskayaV.GrudininM.et al.Assessment of human immune responses to H7" exact="avian influenza" post="virus of pandemic potential: Results from a placebo-controlled, randomized"/>
 <result pre="2007 13.RudenkoL.KiselevaI.NaykhinA.N.ErofeevaM.StukovaM.DoninaS.PetukhovaG.PisarevaM.KrivitskayaV.GrudininM.et al.Assessment of human immune responses to H7 avian" exact="influenza" post="virus of pandemic potential: Results from a placebo-controlled, randomized"/>
 <result pre="placebo-controlled, randomized double-blind phase I study of live attenuated H7N3" exact="influenza" post="vaccinePLoS ONE20149e8796210.1371/journal.pone.008796224533064 14.Isakova-SivakI.StukovaM.ErofeevaM.NaykhinA.DoninaS.PetukhovaG.KuznetsovaV.KiselevaI.SmolonoginaT.DubrovinaI.et al.H2N2 live attenuated influenza vaccine is"/>
 <result pre="live attenuated H7N3 influenza vaccinePLoS ONE20149e8796210.1371/journal.pone.008796224533064 14.Isakova-SivakI.StukovaM.ErofeevaM.NaykhinA.DoninaS.PetukhovaG.KuznetsovaV.KiselevaI.SmolonoginaT.DubrovinaI.et al.H2N2 live attenuated" exact="influenza" post="vaccine is safe and immunogenic for healthy adult volunteersHum."/>
 <result pre="adult volunteersHum. Vaccin. Immunother.20151197098210.1080/21645515.2015.101085925831405 15.De JongeJ.Isakova-SivakI.Van DijkenH.SpijkersS.MouthaanJ.De JongR.SmolonoginaT.RohollP.RudenkoL.H7N9 live attenuated" exact="influenza" post="vaccine is highly immunogenic, prevents virus replication, and protects"/>
 <result pre="is highly immunogenic, prevents virus replication, and protects against severe" exact="bronchopneumonia" post="in ferretsMol. Ther.201624991100210.1038/mt.2016.2326796670 16.RudenkoL.Isakova-SivakI.NaykhinA.KiselevaI.StukovaM.ErofeevaM.KorenkovD.MatyushenkoV.SparrowE.KienyM.P.H7N9 live attenuated influenza vaccine in"/>
 <result pre="protects against severe bronchopneumonia in ferretsMol. Ther.201624991100210.1038/mt.2016.2326796670 16.RudenkoL.Isakova-SivakI.NaykhinA.KiselevaI.StukovaM.ErofeevaM.KorenkovD.MatyushenkoV.SparrowE.KienyM.P.H7N9 live attenuated" exact="influenza" post="vaccine in healthy adults: A randomised, double-blind, placebo-controlled, phase"/>
 <result pre="OrganizationGeneva, Switzerland2002 20.LindstromS.E.CoxN.J.KlimovA.Genetic analysis of human H2N2 and early H3N2" exact="influenza" post="viruses, 1957â€&quot;1972: Evidence for genetic divergence and multiple reassortment"/>
 <result pre="present in unexposed humansPLoS Med.20074e5910.1371/journal.pmed.004005917298168 23.DeshevaY.SychevI.SmolonoginaT.RekstinA.IlyushinaN.LugovtsevV.GoA.LernerA.Anti-neuraminidase antibodies against pandemic A/H1N1" exact="influenza" post="viruses in healthy and influenza-infected individualsPLoS ONE201813e019677110.1371/journal.pone.019677129742168 24.DeshevaY.A.SmolonoginaT.A.DoninaS.A.RudenkoL.G.Serum strain-specific"/>
 <result pre="strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic A/California/07/2009 (H1N1)" exact="influenza" post="in healthy volunteersBMC Res. Notes2015813610.1186/s13104-015-1086-z25889924 25.MontoA.S.PetrieJ.G.CrossR.T.JohnsonE.LiuM.ZhongW.LevineM.KatzJ.M.OhmitS.E.Antibody to influenza virus"/>
 <result pre="A/California/07/2009 (H1N1) influenza in healthy volunteersBMC Res. Notes2015813610.1186/s13104-015-1086-z25889924 25.MontoA.S.PetrieJ.G.CrossR.T.JohnsonE.LiuM.ZhongW.LevineM.KatzJ.M.OhmitS.E.Antibody to" exact="influenza" post="virus neuraminidase: An independent correlate of protectionJ. Infect. Dis.20152121191119910.1093/infdis/jiv19525858957"/>
 <result pre="of antibody production against neuraminidase to the protection afforded by" exact="influenza" post="vaccinesRev. Med. Virol.20122226727910.1002/rmv.171322438243 27.BodewesR.KreijtzJ.H.BaasC.Geelhoed-MierasM.M.de MutsertG.Van AmerongenG.Van den BrandJ.M.FouchierR.A.OsterhausA.D.RimmelzwaanG.F.Vaccination against"/>
 <result pre="vaccinesRev. Med. Virol.20122226727910.1002/rmv.171322438243 27.BodewesR.KreijtzJ.H.BaasC.Geelhoed-MierasM.M.de MutsertG.Van AmerongenG.Van den BrandJ.M.FouchierR.A.OsterhausA.D.RimmelzwaanG.F.Vaccination against human" exact="influenza" post="A/H3N2 virus prevents the induction of heterosubtypic immunity against"/>
 <result pre="prevents the induction of heterosubtypic immunity against lethal infection with" exact="avian influenza" post="A/H5N1 virusPLoS ONE20094e553810.1371/journal.pone.000553819440239 28.LaiJ.C.C.KarunarathnaH.M.WongH.H.PeirisJ.S.NichollsJ.M.Neuraminidase activity and specificity of influenza"/>
 <result pre="the induction of heterosubtypic immunity against lethal infection with avian" exact="influenza" post="A/H5N1 virusPLoS ONE20094e553810.1371/journal.pone.000553819440239 28.LaiJ.C.C.KarunarathnaH.M.WongH.H.PeirisJ.S.NichollsJ.M.Neuraminidase activity and specificity of influenza"/>
 <result pre="avian influenza A/H5N1 virusPLoS ONE20094e553810.1371/journal.pone.000553819440239 28.LaiJ.C.C.KarunarathnaH.M.WongH.H.PeirisJ.S.NichollsJ.M.Neuraminidase activity and specificity of" exact="influenza" post="A virus are influenced by haemagglutinin-receptor bindingEmerg. Microbes Infect.2019832733810.1080/22221751.2019.158103430866786"/>
 <result pre="antihemagglutinin and antineuraminidase antibodies as correlates of protection in an" exact="influenza" post="A/H1N1 virus healthy human challenge modelMBio20167e00417-1610.1128/mBio.00417-1627094330 31.KilbourneE.D.PokornyB.A.JohanssonB.BrettI.MilevY.MatthewsJ.T.Protection of mice"/>
 <result pre="virus healthy human challenge modelMBio20167e00417-1610.1128/mBio.00417-1627094330 31.KilbourneE.D.PokornyB.A.JohanssonB.BrettI.MilevY.MatthewsJ.T.Protection of mice with recombinant" exact="influenza" post="virus neuraminidaseJ. Infect. Dis.200418945946110.1086/38112314745703 32.GartenR.J.DavisC.T.RussellC.A.ShuB.LindstromS.BalishA.SessionsM.XuX.SkepnerE.DeydeV.et al.Antigenic and genetic characteristics"/>
 <result pre="32.GartenR.J.DavisC.T.RussellC.A.ShuB.LindstromS.BalishA.SessionsM.XuX.SkepnerE.DeydeV.et al.Antigenic and genetic characteristics of swine-origin 2009 A (H1N1)" exact="influenza" post="viruses circulating in humansScience200932519720110.1126/science.117622519465683 33.RizzoC.RotaM.C.BellaA.AlfonsiV.DeclichS.CaporaliM.G.RanghiasciA.LapiniG.PiccirellaS.SalmasoS.et al.Cross-reactive antibody responses to"/>
 <result pre="in humansScience200932519720110.1126/science.117622519465683 33.RizzoC.RotaM.C.BellaA.AlfonsiV.DeclichS.CaporaliM.G.RanghiasciA.LapiniG.PiccirellaS.SalmasoS.et al.Cross-reactive antibody responses to the 2009 A/H1N1v" exact="influenza" post="virus in the Italian population in the pre-pandemic periodVaccine2010283558356210.1016/j.vaccine.2010.03.00620307592"/>
 <result pre="in Naturally Infected AdultsClin. Infect. Dis.201910.1093/cid/ciz63931300819 36.BentonD.J.WhartonS.A.MartinS.R.McCauleyJ.W.Role of neuraminidase in" exact="influenza" post="A (H7N9) virus receptor bindingJ. Virol.201791e02293-1610.1128/JVI.02293-1628356530 Figure 1 The"/>
 <result pre="hemagglutination/microneutralization (HI/MN) antibody seroconversions in the paired sera of live" exact="influenza" post="vaccine (LAIV)-vaccinated subjects (â‰¥twofold increase in NI titers; â‰¥fourfold"/>
 <result pre="flu season). (b) Phylogenetic tree of the N1 neuraminidase of" exact="influenza" post="virus isolates belonging to different HA subtypes. (c) NI"/>
 <result pre="in the paired sera collected from convalescents with laboratory confirmed" exact="influenza" post="A (n = 8). antibodies-09-00020-t001_Table 1Table 1 The list"/>
 <result pre="antibodies-09-00020-t001_Table 1Table 1 The list of clinical trials of live" exact="influenza" post="vaccines for use against pandemic and potentially pandemic influenza"/>
 <result pre="live influenza vaccines for use against pandemic and potentially pandemic" exact="influenza" post="viruses. Year Subtype Vaccine Strain â€œWildâ€� Type Virus Genome"/>
 <result pre="[15,16] antibodies-09-00020-t002_Table 2Table 2 The surface antigen compositions of diagnostic" exact="influenza" post="viruses. Subtype HA NA H7N1 A/horse/Prague/1/56 (H7N7) A/New Caledonia/20/99(H1N1)"/>
 <result pre="4Table 4 Pre-existing NI antibodies against pandemic or potentially pandemic" exact="influenza" post="in the sera of non-vaccinated persons. Year NA Subtype"/>
</results>
